National Eye Institute (NEI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Eye Institute (NEI) sits in the top decile of US sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count).
National Eye Institute (NEI): 221 sponsored US clinical trials, 18 recruiting.
National Eye Institute (NEI) sponsors 221 registered US clinical trials on ClinicalTrials.gov, 18 of them currently recruiting, and 179 completed. 11 of these trials are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Age-related Macular Degeneration, with 8 trials.
Top-decile sponsor footprint
National Eye Institute (NEI) ranks in the top decile of sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
179 of 196 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
221 total, page 3 of 5
Family Studies of Uveal Coloboma
NCT00368004
Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy
NCT00411333
Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
NCT00326508
Dynamic Light Scattering to Study Crystalline Proteins in Young Normal Lenses
NCT00304967
Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
NCT00304954
Efalizumab to Treat Uveitis
NCT00280826
Clinical and Molecular Studies in Families With Glaucoma and Related Diseases
NCT00272363
Clinical and Genetic Studies in Families With Myopia and Related Diseases
NCT00272376
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
NCT00265590
Molecular Genetics of Retinal Degenerations
NCT00231010
Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema
NCT00231023
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
NCT00130637
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
NCT00121589
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
NCT00116090
Natural History and Genetic Studies of Usher Syndrome
NCT00106743
Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation
NCT00105404
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
NCT00106132
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
NCT00101764
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
NCT00100009
Visual Cortex Stimulation in Patients With Amblyopia
NCT00097162
Cyclosporine Implant for Ocular Graft-Versus-Host Disease
NCT00102583
Effects of Antioxidants on Human Macular Pigments
NCT00718653
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
NCT00089765
Immune Indicators of Uveitis
NCT00089739
Screening for Research Subjects With Anterior Segment Diseases
NCT00088348
Efficacy of Elevated CD4 Counts on CMV Retinitis
NCT00091884
Helicobacter Pylori and Dry Eye
NCT00083291
Evaluation and Treatment of Eye Complications of Vaccinia Vaccination
NCT00081835
Dynamic Light Scattering for Studying Lens Aging and Cataract Formation
NCT00081991
Daclizumab and Sirolimus to Treat Uveitis
NCT00078689
Evaluation of the Age-Related Eye Disease Study (AREDS) Clinical Lens Grading System
NCT00078299
Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases
NCT00076271
Infliximab to Treat Non-Infectious Scleritis
NCT00075075
Digital Photography to Evaluate Dry Eye
NCT00073099
Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders
NCT00071227
Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases
NCT00357435
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
NCT00070759
Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema
NCT00069056
Optical Coherence Tomography Comparative Study
NCT00069199
Pilot Study: Dynamic Light Scattering Device for Studying Early Changes in Cataract
NCT00067483
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00065455
Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT00346333
Analyses of Existing Framingham Data
NCT00342810
Investigating Age-Related Macular Degeneration
NCT00342251
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00063765
Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy
NCT00060749
Raman Scattering Spectroscopy to Measure Macular Pigment
NCT00060580
Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases
NCT00357071
Genetic Factors in Age-Related Macular Degeneration
NCT00058695
Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts
NCT00056771
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 62 |
| Phase 2 | 24 |
| Phase 3 | 11 |
Therapeutic Areas
What is open in the National Eye Institute (NEI) pipeline
18 recruiting of 221 indexed (8% open); 179 completed (81%).
Phase mix: 11 late (III/IV) vs 86 early (I/II) (early-phase heavy).
Top condition: Age-related Macular Degeneration (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Eye Institute (NEI): open-pipeline peers nationwide
Peers matched on 221 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Eye Institute (NEI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 221 trials (± recruiting share)
- Otsuka Pharmaceutical Development & Commercialization · 221 trials · 4% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
- University of Louisville · 217 trials · 21% recruiting
Sponsors near 8% open enrollment (± trial volume)
- GE Healthcare · 8% recruiting · 99 trials
- HealthPartners Institute · 8% recruiting · 146 trials
- Oregon Research Institute · 8% recruiting · 62 trials
- Arcutis Biotherapeutics · 8% recruiting · 25 trials
Related
What to do with this National Eye Institute (NEI) page
221 registered trials is a research-attention snapshot, not an endorsement of National Eye Institute (NEI) or any single study.
- 18 of National Eye Institute (NEI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Age-related Macular Degeneration is the condition National Eye Institute (NEI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Age-related Macular Degeneration trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Eye Institute (NEI) pipeline card: 221 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.